Stockreport

UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder [Yahoo! Finance]

UCB SA UNSP/ADR  (UCBJY) 
NASDAQ:AMEX Investor Relations: ucb.com/investors
PDF Results underscore the impact of UCB's continued investment in scientific innovation to advance new treatments for DEEs CDKL5 deficiency disorder (CDD) is an ultra-ra [Read more]